While no difference was found in cervical CD4+ T cells or monocytes or their CCR5 expression of the same cohort of women between women with and without FGS, PZQ treatment led to a significant decrease in CD14+ monocytes in both blood and cervical samples. This evidence concerns the gene CD14 and focal segmental glomerulosclerosis.